Diagnosis of breast implant associated anaplastic large cell lymphoma by analysis of cytokines in peri-implant seromas

Am J Hematol. 2023 Nov;98(11):E312-E314. doi: 10.1002/ajh.27055. Epub 2023 Aug 30.

Abstract

More than 1300 women with breast implants have developed an anaplastic large cell lymphoma (ALCL) in fluid (seroma) around their implant. More often, seromas are due to benign causes, for example, capsule contracture, leakage, or trauma. Our report in American Journal of Hematology identified several cytokines (IL-9, IL-10, IL-13) as significantly elevated only in seromas due to ALCL. We further showed that the most robust biomarker, IL-10, could be detected by a lateral flow assay (similar to COVID detection) within minutes allowing physicians to quickly plan management, eliminate or reduce costly testing and patient time away from family. Early detection of ALCL in seromas before infiltration may avoid need for cytotoxic or immunotherapy and is possibly life-saving.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Implants* / adverse effects
  • Breast Neoplasms* / complications
  • Breast Neoplasms* / diagnosis
  • COVID-19 Testing
  • COVID-19* / complications
  • Cytokines
  • Female
  • Humans
  • Interleukin-10
  • Lymphoma, Large-Cell, Anaplastic* / diagnosis
  • Lymphoma, Large-Cell, Anaplastic* / etiology
  • Lymphoma, Large-Cell, Anaplastic* / pathology
  • Seroma / diagnosis
  • Seroma / etiology
  • Seroma / pathology

Substances

  • Interleukin-10
  • Cytokines